PT1754718E - Factor viii resistente à inactivação - Google Patents

Factor viii resistente à inactivação Download PDF

Info

Publication number
PT1754718E
PT1754718E PT06004484T PT06004484T PT1754718E PT 1754718 E PT1754718 E PT 1754718E PT 06004484 T PT06004484 T PT 06004484T PT 06004484 T PT06004484 T PT 06004484T PT 1754718 E PT1754718 E PT 1754718E
Authority
PT
Portugal
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Application number
PT06004484T
Other languages
English (en)
Portuguese (pt)
Inventor
Randal J Kaufman
Steven W Pipe
Kagehiro Amano
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of PT1754718E publication Critical patent/PT1754718E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT06004484T 1996-04-24 1997-04-24 Factor viii resistente à inactivação PT1754718E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PT1754718E true PT1754718E (pt) 2011-07-13

Family

ID=26688196

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06004484T PT1754718E (pt) 1996-04-24 1997-04-24 Factor viii resistente à inactivação

Country Status (10)

Country Link
US (2) US6838437B2 (cg-RX-API-DMAC7.html)
EP (3) EP0910628B1 (cg-RX-API-DMAC7.html)
JP (2) JP3987114B2 (cg-RX-API-DMAC7.html)
AT (2) ATE502958T1 (cg-RX-API-DMAC7.html)
AU (1) AU3202797A (cg-RX-API-DMAC7.html)
CA (1) CA2252896C (cg-RX-API-DMAC7.html)
DE (2) DE69735421T2 (cg-RX-API-DMAC7.html)
DK (1) DK1754718T3 (cg-RX-API-DMAC7.html)
PT (1) PT1754718E (cg-RX-API-DMAC7.html)
WO (1) WO1997040145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833848B1 (en) * 1995-06-12 2001-09-12 Stichting Sanquin Bloedvoorziening Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
JP3987114B2 (ja) 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
ES2395544T3 (es) 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
WO2006108590A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2520586A1 (en) * 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
JP5922141B2 (ja) * 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
DK2768522T3 (en) 2011-10-18 2016-11-14 Csl Behring Gmbh The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
EP2768853A1 (en) 2011-10-18 2014-08-27 CSL Limited Method for improving the stability of purified factor viii after reconstitution
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
KR20150088853A (ko) 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
CA2892750A1 (en) * 2012-11-29 2014-06-05 Bayer Healthcare Llc Monoclonal antibodies agaisnt activated protein c (apc)
EP2988758B1 (en) * 2013-03-15 2018-04-25 Bayer HealthCare LLC Variant factor viii polypeptides and methods of their production and use
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6704420B2 (ja) * 2015-03-06 2020-06-03 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト フォンヴィレブランド因子の半減期を改善するための化合物
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
SG11201903950UA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
CN120865384A (zh) * 2018-10-23 2025-10-31 费城儿童医院 用于调节因子viii功能的组合物和方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
AU2020395323A1 (en) * 2019-12-06 2022-06-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2068728A1 (en) 1989-11-17 1991-05-18 Barbara Chapman Protein complexes having factor viii:c activity and production thereof
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
JP3987114B2 (ja) * 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子

Also Published As

Publication number Publication date
ATE502958T1 (de) 2011-04-15
JP4250661B2 (ja) 2009-04-08
JP2007228973A (ja) 2007-09-13
ATE319817T1 (de) 2006-03-15
JP2000511407A (ja) 2000-09-05
US20060014683A1 (en) 2006-01-19
JP3987114B2 (ja) 2007-10-03
US6838437B2 (en) 2005-01-04
EP1754718A3 (en) 2007-05-16
US20020132306A1 (en) 2002-09-19
EP0910628A1 (en) 1999-04-28
EP0910628B1 (en) 2006-03-08
EP0910628A4 (en) 2001-05-02
EP2202242A1 (en) 2010-06-30
CA2252896A1 (en) 1997-10-30
EP1754718B1 (en) 2011-03-23
CA2252896C (en) 2009-03-10
DE69735421D1 (de) 2006-05-04
AU3202797A (en) 1997-11-12
EP1754718A2 (en) 2007-02-21
DE69735421T2 (de) 2006-10-19
US7459534B2 (en) 2008-12-02
DE69740154D1 (de) 2011-05-05
WO1997040145A1 (en) 1997-10-30
DK1754718T3 (da) 2011-07-18

Similar Documents

Publication Publication Date Title
PT1754718E (pt) Factor viii resistente à inactivação
ATE239789T1 (de) Chimäre prokoagulierende proteine
AU645539B2 (en) A recombinant human factor VIII derivative
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
EP0442961A1 (en) HYBRID PROCOAGULATING PROTEINS.
AU3498189A (en) Fibronectin binding protein
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
AU3793493A (en) Therapeutic domains of von willebrand factor
MX9708426A (es) Polipeptido hk2 de variante estable.
DE69132889D1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
EP0665888A4 (en) ALLERGEN FROM RAYGRASS POLLEN.
EP0576426A4 (cg-RX-API-DMAC7.html)
MX9806041A (es) Proteina purificada sr-p70.
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
NO921219D0 (no) Somatostatin reseptor
WO1995018828A1 (en) Factor viii derivatives